BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 26163610)

  • 21. The Application Value of Serum HE4 in the Diagnosis of Lung Cancer.
    Wang Y; Wang Z; Ding Y; Sun F; Ding X
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2405-2407. PubMed ID: 31450913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarkers in the lung cancer diagnosis: a clinical perspective.
    Li X; Asmitananda T; Gao L; Gai D; Song Z; Zhang Y; Ren H; Yang T; Chen T; Chen M
    Neoplasma; 2012; 59(5):500-7. PubMed ID: 22668014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer.
    Zhao T; Mao G; Chen M
    Comput Math Methods Med; 2021; 2021():1951364. PubMed ID: 34603482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer.
    Zhang ZH; Han YW; Liang H; Wang LM
    Cancer Med; 2015 Nov; 4(11):1633-8. PubMed ID: 26333429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer.
    Sun M; Song J; Zhou Z; Zhu R; Jin H; Ji Y; Lu Q; Ju H
    Dis Markers; 2016; 2016():3823121. PubMed ID: 26880855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of lung cancer based on serum biomarkers by gene expression programming methods.
    Yu Z; Chen XZ; Cui LH; Si HZ; Lu HJ; Liu SH
    Asian Pac J Cancer Prev; 2014; 15(21):9367-73. PubMed ID: 25422226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
    Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
    Zhang L; Liu D; Li L; Pu D; Zhou P; Jing Y; Yu H; Wang Y; Zhu Y; He Y; Li Y; Zhao S; Qiu Z; Li W
    BMC Cancer; 2017 Feb; 17(1):96. PubMed ID: 28152979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].
    Ren Z; Ding HM; Qian X; Pan SY
    Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1426-1434. PubMed ID: 34963239
    [No Abstract]   [Full Text] [Related]  

  • 32. Association of serum levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and disease characteristics in colorectal cancer.
    Zhong W; Yu Z; Zhan J; Yu T; Lin Y; Xia ZS; Yuan YH; Chen QK
    Pathol Oncol Res; 2015 Jan; 21(1):83-95. PubMed ID: 24875250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of Pleural Invasion in Challenging Non-Small-Cell Lung Cancer Patients Using Serum and Imaging Markers.
    Zhu K; Chen L; He C; Lang Y; Kong X; Qu C; Xu S
    Dis Markers; 2020; 2020():6430459. PubMed ID: 32089756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?
    Yang Q; Zhang P; Wu R; Lu K; Zhou H
    Dis Markers; 2018; 2018():2082840. PubMed ID: 30364165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
    Yang J; Tang A; Ma J; Sun X; Ming L
    Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical value of combined determination of serum and pleural effusion level of CEA,CYFRA21-1, TPS in the diagnosis of lung cancer].
    Huang F; Wang XL; Yang L; Yin BX; Geng Y; Li TT
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr; 24(4):370-2. PubMed ID: 18394347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].
    Chen H; Yang X; Liu H; Ma K; Zhong J; Dong Z; Zhuo M; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):589-597. PubMed ID: 28935011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Serum Tumor Markers in Combination for Clinical Diagnosis of Lung Cancer.
    Wu H; Wang Q; Liu Q; Zhang Q; Huang Q; Yu Z
    Clin Lab; 2020 Mar; 66(3):. PubMed ID: 32162867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum cyfra21-1 as a biomarker in patients with nonsmall cell lung cancer.
    Zhao H; Shi X; Liu J; Chen Z; Wang G
    J Cancer Res Ther; 2014 Nov; 10 Suppl():C215-7. PubMed ID: 25450285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.